Karolinska Institutet
- Address
- lock Available on a paid plan
Infectious Diseases and Neurological Infections
At Karolinska Institutet, research in bacterial infections and nervous system diseases includes studies on brain abscess, with a focus on finding effective treatment options that may support recovery while maintaining good clinical outcomes.
- Comparing oral and intravenous antibiotic treatment for bacterial brain abscess
- Evaluating whether a simpler treatment approach can be as effective as standard care
This work is aimed at improving treatment convenience and effectiveness for serious intracranial infection.
Autoimmune and Connective Tissue Disease Research
Clinical research in immune system diseases and skin and connective tissue diseases includes diffuse cutaneous systemic sclerosis, where investigators are studying strategies to improve survival and reduce the risk of major organ damage in early disease.
- Testing stem cell transplantation as an early treatment option
- Assessing how treatment strategies may help prevent organ failure
The goal is to identify a more effective approach for a severe autoimmune condition that can affect multiple organs.
Dermatology and Rare Genetic Skin Disorders
Work in skin and connective tissue diseases at this site also covers Netherton syndrome, a rare inherited disorder, with trials designed to assess whether a new topical therapy can safely control symptoms and improve patient well-being.
- Studying a topical treatment for clinical safety and effectiveness
- Exploring symptom control in a rare skin disease
This research supports the development of better options for people living with a difficult-to-manage dermatologic condition.
Hematology and Cancer Therapeutics
Clinical trials in hemic and lymphatic diseases focus on hematological malignancies, including leukemia and lymphoma, with research aimed at testing the safety and potential benefit of new cancer treatments for patients with advanced or relapsed disease.
- Evaluating a new therapy for blood cancers such as AML, ALL, DLBCL, and multiple myeloma
- Assessing treatment safety and tolerability in difficult-to-treat malignancies
These studies reflect an effort to expand options for patients with aggressive cancers who have limited standard treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Aalborg University Hospital1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Karolinska Institutet
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy of Autologous Hematopoietic Stem Cell Transplantation Versus Immunosuppressive Therapy in Early Diffuse Cutaneous Systemic Sclerosis | Universitair Medisch Centrum Utrecht | Phase III | Recruiting | Aug 2020 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amoxicillin | 1 | Unknown | 2021-05-02 | 2021-05-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.